Folia Neuropathologica

Cepharanthine enhances functional recovery in spinal cord injury by attenuating NLRP3 inflammasome activation through the Nrf2/HO-1 and NF-κB pathways

Li Wang 1
,
Kuanhong Shen 1
,
Guanghui Su 1
,
Jun Qian 1

  1. Hengyang Central Hospital, China

Folia Neuropathol 2026; 64 (2)

DOI: https://doi.org/10.5114/fn.2026.162081
Data publikacji online: 2026/08/04
Article file
Cepharanthine Qian 02037.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 181: 56-87.
  2. SCI Facts and Figures. J Spinal Cord Med 2017; 406: 872-873.
  3. Ahuja CS, Nori S, Tetreault L, Wilson J, Kwon B, Harrop J, Choi D, Fehlings MG. Traumatic spinal cord injury-repair and regeneration. Neurosurgery 2017; 80: S9-S22.
  4. Anjum A, Yazid MD, Fauzi Daud M, Idris J, Ng AMH, Selvi Naicker A, Ismail OHR, Athi Kumar RK, Lokanathan Y. Spinal cord injury: Pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 2020; 21: 7533.
  5. Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 2022; 14: 879021.
  6. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012; 11: CD001046.
  7. Chay W, Kirshblum S. Predicting outcomes after spinal cord injury. Phys Med Rehabil Clin N Am 2020; 313: 331-343.
  8. Chen G, Li J, Liu H, Zhou H, Liu M, Liang D, Meng Z, Gan H, Wu Z, Zhu X, Han P, Liu T, Gu R, Liu S, Dou G. Cepharanthine ameliorates pulmonary fibrosis by inhibiting the NF-κB/NLRP3 pathway, fibroblast-to-myofibroblast transition and inflammation. Molecules 2023; 28: 753.
  9. Chen S, Ye J, Chen X, Shi J, Wu W, Lin W, Lin W, Li Y, Fu H, Li S. Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3. J Neuroinflammation 2018; 151: 150.
  10. Chen Y, Wu L, Shi M, Zeng D, Hu R, Wu X, Han S, He K, Xu H, Shao X, Ma R. Electroacupuncture inhibits NLRP3 activation by regulating CMPK2 after spinal cord injury. Front Immunol 2022; 13: 788556.
  11. Ding Y, Chen Q. The NF-κB Pathway: a focus on inflammatory responses in spinal cord injury. Mol Neurobiol 2023; 609: 5292-5308.
  12. Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol 2023; 41: 301-316.
  13. Ge MH, Tian H, Mao L, Li DY, Lin JQ, Hu HS, Huang SC, Zhang CJ, Mei XF. Zinc attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury by activating Nrf2/GPX4 defense pathway. CNS Neurosci Ther 2021; 279: 1023-1040.
  14. Gu HY, Liu N. Mechanism of effect and therapeutic potential of NLRP3 inflammasome in spinal cord injury. Exp Neurol 2024; 384: 115059.
  15. Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF-B in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther 2024; 91: 53.
  16. Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol 2021; 189: 2114-2127.
  17. Jin W, Botchway BOA, Liu X. Curcumin can activate the Nrf2/HO-1 signaling pathway and scavenge free radicals in spinal cord injury treatment. Neurorehabil Neural Repair 2021; 357: 576-584.
  18. Liang D, Wang W, Chen G, Li J, Dou G, Gan H, Han P, Du L, Gu R. Cepharanthine dry powder inhaler for the treatment of acute lung injury. Molecules 2023; 28: 4441.
  19. Liu K, Hong B, Wang S, Lou F, You Y, Hu R, Shafqat A, Fan H, Tong Y. Pharmacological activity of cepharanthine. Molecules 2023; 28: 5019.
  20. Liu Z, Tu K, Zou P, Liao C, Ding R, Huang Z, Huang Z, Yao X, Chen J, Zhang Z. Hesperetin ameliorates spinal cord injury by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. Int Immunopharmacol 2023; 118: 110103.
  21. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 2015; 42: 20-27.
  22. Mansouri A, Reiner Ž, Ruscica M, Tedeschi-Reiner E, Radbakhsh S, Bagheri Ekta M, Sahebkar A. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J Clin Med 2022; 11: 1313.
  23. Mokhtari T, Uludag K. Role of NLRP3 inflammasome in post-spinal-cord-injury anxiety and depression: molecular mechanisms and therapeutic implications. ACS Chem Neurosci 2023; 151: 56-70.
  24. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-B signaling. Cell Res 2010; 211: 103-115.
  25. O’Rourke SA, Shanley LC, Dunne A. The Nrf2-HO-1 system and inflammaging. Front Immunol 2024; 15: 1457010.
  26. Quadri SA, Farooqui M, Ikram A, Zafar A, Khan MA, Suriya SS, Claus CF, Fiani B, Rahman M, Ramachandran A, Armstrong IIT, Taqi MA, Mortazavi MM. Recent update on basic mechanisms of spinal cord injury. Neurosurg Rev 2018; 432: 425-441.
  27. Shi L, Wang S, Zhang S, Wang J, Chen Y, Li Y, Liu Z, Zhao S, Wei B, Zhang L. Research progress on pharmacological effects and mechanisms of cepharanthine and its derivatives. Naunyn Schmiedebergs Arch Pharmacol 2023; 39611: 2843-2860.
  28. Wang J, Zhang F, Xu H, Yang H, Shao M, Xu S, Lyu F. TLR4 aggravates microglial pyroptosis by promoting DDX3X-mediated NLRP3 inflammasome activation via JAK2/STAT1 pathway after spinal cord injury. Clin Transl Med 2022; 126: e894.
  29. Wang L, Ren W, Wu Q, Liu T, Wei Y, Ding J, Zhou C, Xu H, Yang S. NLRP3 inflammasome activation: a therapeutic target for cerebral ischemia-reperfusion injury. Front Mol Neurosci 2022; 15: 847440.
  30. Wang YF, Zu JN, Li J, Chen C, Xi CY, Yan JL. Curcumin promotes the spinal cord repair via inhibition of glial scar formation and inflammation. Neurosci Lett 2013; 560: 51-56.
  31. Yao M, Zhang C, Ni L, Ji X, Hong J, Chen Y, Wang J, Li C, Lin J, Lu T, Sheng Y, Sun M, Shi M, Zhou C, Cai X. Cepharanthine ameliorates chondrocytic inflammation and osteoarthritis via regulating the MAPK/NF-κB-autophagy pathway. Front Pharmacol 2022; 13: 854239.
  32. Yao R, Ren L, Wang S, Zhang M, Yang K. Euxanthone inhibits traumatic spinal cord injury via anti-oxidative stress and suppression of p38 and PI3K/Akt signaling pathway in a rat model. Transl Neurosci 2021; 121: 114-126.
  33. Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res 2021; 34: 43-63.
  34. Zhang X, Wang Z, Zheng Y, Yu Q, Zeng M, Bai L, Yang L, Guo M, Jiang X, Gan J. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review). Int J Mol Med 2023; 51: 35.
  35. Zhang X, Yu Y, Lei H, Cai Y, Shen J, Zhu P, He Q, Zhao M. The Nrf-2/HO-1 signaling axis: a ray of hope in cardiovascular diseases. Cardiol Res Pract 2020; 2020: 5695723.
  36. Zhang Y, Al Mamun A, Yuan Y, Lu Q, Xiong J, Yang S, Wu C, Wu Y, Wang J. Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review). Mol Med Rep 2021; 23: 417.
  37. Zhao J, Piao X, Wu Y, Liang S, Han F, Liang Q, Shao S, Zhao D. Cepharanthine attenuates cerebral ischemia/reperfusion injury by reducing NLRP3 inflammasome-induced inflammation and oxidative stress via inhibiting 12/15-LOX signaling. Biomed Pharmacother 2020; 127: 110151.
  38. Zhen Y, Zhang H. NLRP3 Inflammasome and inflammatory bowel disease. Front Immunol 2019; 10: 276.
  39. Zhou P, Zhang X, Xin X, Yang J, Pan Q, Liu C, Liu Y, Yu X, Li Z, Jiao G, Liu X. Click chemistry-conjugated protein-drug micelles with anti-ferroptotic and anti-inflammatory properties promote regeneration in spinal cord injury. Chem Eng J 2022; 428: 132118.
Copyright: © 2026 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications